Patients with solid tumors and a higher body mass index (BMI) experience improved survival after receiving anti-PD1 antibodies.
The predictive role of BMI in Hodgkin Lymphoma (HL), the most sensitive malignancy to PD1-blockade, remains unclear.
We analyzed the association between BMI and survival outcomes in patients treated with the anti-PD-1 antibody nivolumab within the CheckMate 205 study.
Patients with a lower BMI (<24.03â€‰kg/m
